Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 10/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376534 | 0.87 | MET (1.00) | METCNR1KDREPHX2 | |
| SCHEMBL14205652 | 0.81 | MET (0.69) | METCNR1KDREPHX2SCN3A | |
| SCHEMBL12410273 | 0.79 | MET (0.65) | METCNR1KDREPHX2PDGFRA | |
| SCHEMBL12376537 | 0.77 | MET (1.00) | METKDRPDGFRAKITBRAF | |
| SCHEMBL4382403 | 0.71 | MET (0.55) | METCNR1KDREPHX2BRAF | |
| SCHEMBL3174410 | 0.71 | MET (0.55) | METCNR1KDREPHX2BRAF | |
| SCHEMBL22834156 | 0.69 | CNR1 (1.00) | METCNR1EPHX2 | |
| SCHEMBL22834265 | 0.69 | CNR1 (1.00) | METCNR1EPHX2 | |
| SCHEMBL22834153 | 0.69 | CNR1 (1.00) | METCNR1EPHX2 | |
| SCHEMBL5093594 | 0.69 | MET (0.69) | METKDRPDGFRAKITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MET 142/4885CNR1 347/4885KDR 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.